Biogen Inc. (FRA:IDP)
117.05
0.00 (0.00%)
Last updated: Sep 30, 2025, 9:06 AM CET
Biogen Revenue
Biogen had revenue of $2.65B USD in the quarter ending June 30, 2025, with 7.33% growth. This brings the company's revenue in the last twelve months to $10.00B, up 3.36% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$10.00B
Revenue Growth
+3.36%
P/S Ratio
2.06
Revenue / Employee
$1.31M
Employees
7,605
Market Cap
17.50B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 78.30B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Rheinmetall AG | 10.67B |
Siemens Energy AG | 38.39B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Deutsche Bank Aktiengesellschaft | 30.07B |
Biogen News
- 2 days ago - “LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China - GlobeNewsWire
- 6 days ago - Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 6 days ago - LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia - GlobeNewsWire
- 7 days ago - US FDA declines to approve higher-dose of Biogen's genetic disorder drug - Reuters
- 7 days ago - Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen - GlobeNewsWire
- 12 days ago - A Look Into Biogen Inc's Price Over Earnings - Benzinga
- 12 days ago - Biogen (BIIB) to Acquire Alcyone Therapeutics for $85M - GuruFocus
- 12 days ago - December 19th Options Now Available For Biogen (BIIB) - Nasdaq